Selection and testing of the suitability of antigens for neurodegeneration diagnostics (Q10677)

From EU Knowledge Graph
Revision as of 15:18, 22 October 2020 by DG Regio (talk | contribs) (‎Created claim: summary (P836): The project will include selection and characterisation of antigens for the diagnosis of neurodegenerative diseases, taking into account their commercial availability or possible preparation, the state of intellectual property rights and their intended use for the differential diagnosis of the intended diseases. Selected antigens will be further verified on panels of real samples with a known diagnosis. a., translated_summary)
Jump to navigation Jump to search
Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
Selection and testing of the suitability of antigens for neurodegeneration diagnostics
Project in Czech Republic financed by DG Regio

    Statements

    0 references
    189,000.0 Czech koruna
    0 references
    7,560.0 Euro
    10 January 2020
    0 references
    252,000.0 Czech koruna
    0 references
    10,080.0 Euro
    10 January 2020
    0 references
    75 percent
    0 references
    8 March 2017
    0 references
    31 December 2017
    0 references
    31 December 2017
    0 references
    VIDIA spol. s r.o.
    0 references
    0 references

    49°59'0.49"N, 14°30'9.11"E
    0 references
    25250
    0 references
    V rámci projektu bude proveden výběr a charakterizace antigenů pro diagnostiku neurodegenerativních onemocnění, jednak s ohledem na jejich komerční dostupnost, popř. možnou vlastní přípravu, na stav práv duševního vlastnictví a jednak s ohledem na jejich předpokládané využití pro diferenciální diagnostiku zamýšlených onemocnění. Vybrané antigeny budou dále ověřeny na panelech reálných vzorků se známou diagnózou. a. (Czech)
    0 references
    The project will include selection and characterisation of antigens for the diagnosis of neurodegenerative diseases, taking into account their commercial availability or possible preparation, the state of intellectual property rights and their intended use for the differential diagnosis of the intended diseases. Selected antigens will be further verified on panels of real samples with a known diagnosis. a. (English)
    22 October 2020
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/16_045/0009746
    0 references